MICHAEL MCNAMARA: Open Payments
NPI 1861477259 · MANCHESTER, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$255,678 in 303 payments from 14 companies in 2025. Trend: 2023 $110,986 · 2024 $164,244 · 2025 $255,678
Speaker / faculty: $163,889Consulting: $31,981Travel & lodging: $29,738Honoraria: $21,725Food & beverage: $8,346
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 60 | $62,055 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 42 | $45,373 |
| Otsuka America Pharmaceutical, Inc. | 31 | $37,810 |
| Neurocrine BioSciences, Inc. | 35 | $37,807 |
| Axsome Therapeutics, Inc. | 26 | $23,872 |
| Alkermes, Inc. | 38 | $17,499 |
| Teva Pharmaceuticals USA, Inc. | 15 | $14,895 |
| Janssen Pharmaceuticals, Inc | 20 | $13,069 |
| ABBVIE INC. | 8 | $2,475 |
| Vanda Pharmaceuticals Inc. | 24 | $455 |
Products named: COBENFY, CAPLYTA, INGREZZA, REXULTI, Auvelity, LYBALVI, UZEDY, INVEGA SUSTENNA.
Industry payments across NH — which companies pay providers there.
